Platelet aggregation inhibitors: Difference between revisions
Jump to navigation
Jump to search
imported>Robert Badgett No edit summary |
imported>Robert Badgett |
||
| Line 10: | Line 10: | ||
===Glycoprotein IIb/IIIa inhibitors=== | ===Glycoprotein IIb/IIIa inhibitors=== | ||
Inhibitors of the [[platelet glycoprotein GPIIb-IIIa complex]] include eptifibatide, tirofiban, and the monoclonal antibody abciximab. | Inhibitors of the [[platelet glycoprotein GPIIb-IIIa complex]] (GPIs) include eptifibatide, tirofiban, and the monoclonal antibody abciximab. | ||
===Thienopyridines=== | ===Thienopyridines=== | ||
Revision as of 12:14, 8 January 2010
Platelet aggregation inhibitors, also called antiplatelet drugs, are "drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system."[1]
Classification
Adenosine diphosphate (ADP) blocker
This includes dipyrimadole.
Cyclooxygenase-1 blockers
Cyclooxygenase-1 blockers include aspirin.
Glycoprotein IIb/IIIa inhibitors
Inhibitors of the platelet glycoprotein GPIIb-IIIa complex (GPIs) include eptifibatide, tirofiban, and the monoclonal antibody abciximab.
Thienopyridines
Thienopyridines include clopidogrel, ticlopidine, and the prodrug prasugrel.[2] They inhibit the ADP receptor.
References
- ↑ Anonymous (2024), Platelet aggregation inhibitors (English). Medical Subject Headings. U.S. National Library of Medicine.
- ↑ Sudlow CL, Mason G, Maurice JB, Wedderburn CJ, Hankey GJ (2009). "Thienopyridine derivatives versus aspirin for preventing stroke and other serious vascular events in high vascular risk patients.". Cochrane Database Syst Rev (4): CD001246. DOI:10.1002/14651858.CD001246.pub2. PMID 19821273. Research Blogging.